Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 920686
                    [Title] => Despite setbacks, Alzheimer’s tx pipeline is full
                    [Summary] => 
More than 60 drugs remain in the developmental pipeline for Alzheimer’s disease, although the past several years have seen numerous once-promising agents bite the dust.

                    [DatePublished] => 2013-03-17 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

CEREBROLYSIN

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 920686
                    [Title] => Despite setbacks, Alzheimer’s tx pipeline is full
                    [Summary] => 
More than 60 drugs remain in the developmental pipeline for Alzheimer’s disease, although the past several years have seen numerous once-promising agents bite the dust.

                    [DatePublished] => 2013-03-17 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

Despite setbacks, Alzheimer’s tx pipeline is full

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | March 17, 2013 - 12:00am

More than 60 drugs remain in the developmental pipeline for Alzheimer’s disease, although the past several years have seen numerous once-promising agents bite the dust.

Opinion